FPM supports the ABPI’s position on Legitimate Interests

FPM is supporting the ABPI’s call championing the use of ‘Legitimate Interests’ to boost transparency.

The ABPI has today released new guidance to pharmaceutical companies using Disclosure UK to boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry.

Vice President of FPM Dr Sheuli Porkess said, “Ethics and transparency are key principles within pharmaceutical medicine and FPM welcomes ongoing work to promote transparency of collaborations between industry and healthcare professionals.”